معرفی
William K Decker, Ph.D. serves as Associate Professor in the Department of Pathology & Immunology at Baylor College of Medicine's School of Medicine, and is an active member of the Dan L Duncan Comprehensive Cancer Center in Houston, Texas.
- BS from Tufts University (1994)
- PhD from Baylor College of Medicine (2001)
Decker's research focuses on cancer immunotherapy, particularly dendritic cell vaccination strategies and T-helper cell polarization mechanisms. His work explores how innate immune signaling pathways regulate antitumor immunity and how these can be harnessed for therapeutic interventions. A significant portion of his research investigates the role of dendritic cells in bridging innate and adaptive immunity, with applications in both oncology and infectious disease contexts. His laboratory has developed novel approaches combining chemo-immunotherapy and vaccine adjuvants to overcome tumor immune evasion.
Analysis of his publication record reveals consistent focus on translational immunology, with recurring themes in T-cell differentiation, vaccine adjuvant development, and microenvironment modulation. His work spans basic mechanistic studies of immune regulation to preclinical therapeutic models, including innovative canine cancer studies that bridge veterinary and human medicine.
- Contributing author to Halifax Project's integrative cancer prevention framework
- Multiple invited review articles in Seminars in Cancer Biology and Carcinogenesis
Decker has established collaborative research programs focusing on dendritic cell therapeutics for immunocompromised patients, including novel approaches for influenza prophylaxis in high-risk populations. His work with cord blood-derived immune cells demonstrates particular innovation in developing cellular immunotherapies for challenging clinical scenarios. The laboratory maintains active investigations into immune evasion mechanisms and strategies to overcome therapeutic resistance in solid tumors and hematologic malignancies.
Current research efforts include developing combination immunotherapy approaches for pancreatic cancer and investigating AIMp1's role in TH1 polarization for enhanced antitumor immunity. The laboratory maintains strong translational focus with multiple projects in preclinical development stages.
